Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study

Inclusion Criteria

• •1. Newly diagnosed or relapsed PTCL patients by pathology, and / or cytology examination, which are required to receive chemotherapy;
• •2. At least 1 single size measurable lesions, CT, MRI, Bultrasound scan or PET-CT scan shows more than 15mm；
• •3. Physical condition is good: ECOG score between 0-2 points；
• •4. The expected survival time is more than 3 months；
• •5. Age 18 years or older,unlimited gender；
• •6. Fit chemotherapy indications and basic requirements, including normal peripheral hemogram,no obvious abnormal function of heart, liver and kidney, normal ECG;no great trauma without healing；
• •The test indicators must fit the following requirements:
• •Cardiac ultrasound LVEF≥50%； Peripheral blood：WBC≥3.5×109/L，PLT≥70×109/L，Hb≥80g/L Renal function：Cr≤2.0×UNL（Upper limit of normal value） Liver function：BIL≤2.0×UNL，ALT/AST≤2.5×UNL
• •7. No serious allergic reaction to biological agents, especially E. coli gene engineering products；
• •8. Voluntary participation, good compliance, cooperate with the experimental observation, and sign a written informed consent。